U.S. markets closed

Idera Pharmaceuticals, Inc. (IDRA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.1000+0.0200 (+1.85%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.0800
Open1.0600
Bid1.0900 x 3100
Ask1.1300 x 1800
Day's Range1.0100 - 1.1300
52 Week Range1.0100 - 6.1400
Volume2,298,606
Avg. Volume3,030,856
Market Cap46.5M
Beta (5Y Monthly)1.89
PE Ratio (TTM)N/A
EPS (TTM)-3.3310
Earnings DateMar 01, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Latest Biotech Flop Shows Risks of Trading in Penny Stocks
    Bloomberg

    Latest Biotech Flop Shows Risks of Trading in Penny Stocks

    (Bloomberg) -- Wall Street didn’t see this one coming but retail traders might have, as one tiny biotech saw its value sliced in half overnight on disappointing results for its only medicine in clinical testing.Before new data on an experimental drug combination for skin cancer sent Idera Pharmaceuticals Inc. into a tailspin, every analyst tracked by Bloomberg recommended buying the stock. The average price target among the five brokers following the drug developer was $9, suggesting a roughly 70% return over Thursday’s closing price.But after the drug missed a key goal in a late-stage trial, the company saw its shares plunge by as much as 65%, the biggest intraday drop in eight years. Every one of those analysts cut their rating in the past 24 hours, now recommending investors hold onto the stock. So far, none have recommended selling the Cambridge, Massachusetts-based drug maker.In Idera retail trading, “the last couple months have seen persistent selling with the occasional pop higher,” Eric Liu, the co-founder of Vanda Research said in an email. Data from VandaTrack, a unit of Vanda Research, shows that retail traders cumulatively sold off about 79,000 shares in March, the heaviest selling happened on March 17, when over 106,000 shares were dumped by day traders.In this case, Main Street may have been wiser than Wall Street and Idera’s top investors -- funds tied to the Beirut-based Pillar Invest Corp. and a hedge fund run by the billionaire health-care investor brothers Julian and Felix Baker. Today’s about face should sound an alarm for retail investors using their stimulus checks to dabble in penny stocks. For those chasing after quick returns, biotechs may be especially risky as the chances of successfully getting a new drug from the earliest stage of human testing to regulatory approval are about one in 10.Meme stocks and tiny biotechs drove Nasdaq trading volumes on Friday as stocks like Clovis Oncology Inc., SuperCom Ltd, Senestech Inc and Hall of Fame Resort & Entertaiment Co. rallied.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Why Idera Pharmaceuticals Stock Is Crashing Today
    Motley Fool

    Why Idera Pharmaceuticals Stock Is Crashing Today

    Shares of Idera Pharmaceuticals (NASDAQ: IDRA) were crashing 63.5% at 10:49 a.m. EDT on Friday. The plunge came after the company announced disappointing results Thursday from a late-stage study of tilsotolimod in combination with Bristol Myers Squibb's Yervoy in treating advanced melanoma. Idera had hoped that the tilsotolimod-Yervoy combo would sail through its pivotal study.

  • Benzinga

    Benzinga's Top Ratings Upgrades, Downgrades For March 19, 2021

    Upgrades Argus Research upgraded the previous rating for Nucor Corp (NYSE:NUE) from Hold to Buy. Nucor earned $1.30 in the fourth quarter, compared to $0.52 in the year-ago quarter. The current stock performance of Nucor shows a 52-week-high of $72.22 and a 52-week-low of $27.52. Moreover, at the end of the last trading period, the closing price was at $70.37. B of A Securities upgraded the previous rating for Petco Health and Wellness Co Inc (NASDAQ:WOOF) from Neutral to Buy. In the fourth quarter, Petco Health and Wellness earned $0.17. At the moment, the stock has a 52-week-high of $31.08 and a 52-week-low of $17.86. Petco Health and Wellness closed at $22.53 at the end of the last trading period. According to Edward Jones, the prior rating for Progressive Corp (NYSE:PGR) was changed from Hold to Buy. For the fourth quarter, Progressive had an EPS of $1.57, compared to year-ago quarter EPS of $1.81. The stock has a 52-week-high of $102.05 and a 52-week-low of $62.18. At the end of the last trading period, Progressive closed at $90.27. For EVO Payments Inc (NASDAQ:EVOP), Compass Point upgraded the previous rating of Neutral to Buy. For the fourth quarter, EVO Payments had an EPS of $0.23, compared to year-ago quarter EPS of $0.24. The stock has a 52-week-high of $31.99 and a 52-week-low of $10.12. At the end of the last trading period, EVO Payments closed at $27.85. For SolarEdge Technologies Inc (NASDAQ:SEDG), Susquehanna upgraded the previous rating of Neutral to Positive. SolarEdge Technologies earned $0.98 in the fourth quarter, compared to $1.65 in the year-ago quarter. The current stock performance of SolarEdge Technologies shows a 52-week-high of $377.00 and a 52-week-low of $67.02. Moreover, at the end of the last trading period, the closing price was at $266.49. For Enphase Energy Inc (NASDAQ:ENPH), Susquehanna upgraded the previous rating of Neutral to Positive. For the fourth quarter, Enphase Energy had an EPS of $0.51, compared to year-ago quarter EPS of $0.39. The current stock performance of Enphase Energy shows a 52-week-high of $229.04 and a 52-week-low of $21.49. Moreover, at the end of the last trading period, the closing price was at $148.48. Barclays upgraded the previous rating for Ford Motor Co (NYSE:F) from Equal-Weight to Overweight. In the fourth quarter, Ford Motor showed an EPS of $0.34, compared to $0.12 from the year-ago quarter. The current stock performance of Ford Motor shows a 52-week-high of $13.62 and a 52-week-low of $3.96. Moreover, at the end of the last trading period, the closing price was at $12.50. For Starbucks Corp (NASDAQ:SBUX), Wedbush upgraded the previous rating of Neutral to Outperform. For the first quarter, Starbucks had an EPS of $0.61, compared to year-ago quarter EPS of $0.79. The stock has a 52-week-high of $112.34 and a 52-week-low of $50.02. At the end of the last trading period, Starbucks closed at $107.62. According to Jefferies, the prior rating for Navient Corp (NASDAQ:NAVI) was changed from Hold to Buy. For the fourth quarter, Navient had an EPS of $0.97, compared to year-ago quarter EPS of $0.67. The current stock performance of Navient shows a 52-week-high of $13.70 and a 52-week-low of $4.07. Moreover, at the end of the last trading period, the closing price was at $12.94. For Keurig Dr Pepper Inc (NASDAQ:KDP), JP Morgan upgraded the previous rating of Neutral to Overweight. For the fourth quarter, Keurig Dr Pepper had an EPS of $0.39, compared to year-ago quarter EPS of $0.35. The current stock performance of Keurig Dr Pepper shows a 52-week-high of $34.23 and a 52-week-low of $18.98. Moreover, at the end of the last trading period, the closing price was at $33.89. For National Grid PLC (NYSE:NGG), HSBC upgraded the previous rating of Hold to Buy. The current stock performance of National Grid shows a 52-week-high of $63.78 and a 52-week-low of $44.29. Moreover, at the end of the last trading period, the closing price was at $58.05. For HeadHunter Group PLC (NASDAQ:HHR), JP Morgan upgraded the previous rating of Underweight to Neutral. In the fourth quarter, HeadHunter Group showed an EPS of $0.18, compared to $0.24 from the year-ago quarter. At the moment, the stock has a 52-week-high of $37.29 and a 52-week-low of $12.25. HeadHunter Group closed at $36.45 at the end of the last trading period. For The Hartford Financial Services Group Inc (NYSE:HIG), Credit Suisse upgraded the previous rating of Neutral to Outperform. In the fourth quarter, Hartford Finl Servs Gr showed an EPS of $1.76, compared to $1.43 from the year-ago quarter. The stock has a 52-week-high of $68.95 and a 52-week-low of $19.04. At the end of the last trading period, Hartford Finl Servs Gr closed at $68.53. Goldman Sachs upgraded the previous rating for Evercore Inc (NYSE:EVR) from Buy to Conviction Buy. Evercore earned $5.67 in the fourth quarter, compared to $2.72 in the year-ago quarter. At the moment, the stock has a 52-week-high of $144.13 and a 52-week-low of $33.25. Evercore closed at $138.76 at the end of the last trading period. Mizuho upgraded the previous rating for Paramount Group Inc (NYSE:PGRE) from Underperform to Neutral. For the fourth quarter, Paramount Group had an EPS of $0.24, compared to year-ago quarter EPS of $0.26. At the moment, the stock has a 52-week-high of $10.54 and a 52-week-low of $5.54. Paramount Group closed at $10.36 at the end of the last trading period. See all analyst ratings upgrades. Downgrades According to MKM Partners, the prior rating for The Hartford Financial Services Group Inc (NYSE:HIG) was changed from Buy to Neutral. In the fourth quarter, Hartford Finl Servs Gr showed an EPS of $1.76, compared to $1.43 from the year-ago quarter. At the moment, the stock has a 52-week-high of $68.95 and a 52-week-low of $19.04. Hartford Finl Servs Gr closed at $68.53 at the end of the last trading period. According to Wedbush, the prior rating for Idera Pharmaceuticals Inc (NASDAQ:IDRA) was changed from Outperform to Neutral. For the fourth quarter, Idera Pharmaceuticals had an EPS of $0.22, compared to year-ago quarter EPS of $1.36. The current stock performance of Idera Pharmaceuticals shows a 52-week-high of $6.14 and a 52-week-low of $1.05. Moreover, at the end of the last trading period, the closing price was at $5.21. According to William Blair, the prior rating for Acutus Medical Inc (NASDAQ:AFIB) was changed from Outperform to Market Perform. In the fourth quarter, Acutus Medical earned $0.89. The stock has a 52-week-high of $38.99 and a 52-week-low of $15.58. At the end of the last trading period, Acutus Medical closed at $16.83. For Idera Pharmaceuticals Inc (NASDAQ:IDRA), Barclays downgraded the previous rating of Overweight to Equal-Weight. In the fourth quarter, Idera Pharmaceuticals showed an EPS of $0.22, compared to $1.36 from the year-ago quarter. At the moment, the stock has a 52-week-high of $6.14 and a 52-week-low of $1.05. Idera Pharmaceuticals closed at $5.21 at the end of the last trading period. JMP Securities downgraded the previous rating for Idera Pharmaceuticals Inc (NASDAQ:IDRA) from Outperform to Market Perform. Idera Pharmaceuticals earned $0.22 in the fourth quarter, compared to $1.36 in the year-ago quarter. At the moment, the stock has a 52-week-high of $6.14 and a 52-week-low of $1.05. Idera Pharmaceuticals closed at $5.21 at the end of the last trading period. Goldman Sachs downgraded the previous rating for Houlihan Lokey Inc (NYSE:HLI) from Buy to Neutral. Houlihan Lokey earned $1.77 in the third quarter, compared to $0.88 in the year-ago quarter. The stock has a 52-week-high of $73.26 and a 52-week-low of $42.86. At the end of the last trading period, Houlihan Lokey closed at $68.01. According to JP Morgan, the prior rating for Acutus Medical Inc (NASDAQ:AFIB) was changed from Overweight to Neutral. Interestingly, in the fourth quarter, Acutus Medical's EPS was $0.89. The current stock performance of Acutus Medical shows a 52-week-high of $38.99 and a 52-week-low of $15.58. Moreover, at the end of the last trading period, the closing price was at $16.83. According to Deutsche Bank, the prior rating for Arthur J. Gallagher & Co (NYSE:AJG) was changed from Buy to Hold. For the fourth quarter, Arthur J. Gallagher had an EPS of $0.88, compared to year-ago quarter EPS of $0.58. At the moment, the stock has a 52-week-high of $129.12 and a 52-week-low of $65.09. Arthur J. Gallagher closed at $126.48 at the end of the last trading period. For Blackstone Group Inc (NYSE:BX), Oppenheimer downgraded the previous rating of Outperform to Perform. In the fourth quarter, Blackstone Group showed an EPS of $1.13, compared to $0.71 from the year-ago quarter. The stock has a 52-week-high of $76.25 and a 52-week-low of $33.00. At the end of the last trading period, Blackstone Group closed at $73.04. For U.S. Bancorp (NYSE:USB), Baird downgraded the previous rating of Outperform to Neutral. In the fourth quarter, U.S. Bancorp showed an EPS of $0.95, compared to $1.08 from the year-ago quarter. At the moment, the stock has a 52-week-high of $57.02 and a 52-week-low of $28.36. U.S. Bancorp closed at $56.29 at the end of the last trading period. For Molson Coors Beverage Co (NYSE:TAP), JP Morgan downgraded the previous rating of Neutral to Underweight. Molson Coors Beverage earned $0.40 in the fourth quarter, compared to $1.02 in the year-ago quarter. The current stock performance of Molson Coors Beverage shows a 52-week-high of $56.10 and a 52-week-low of $32.11. Moreover, at the end of the last trading period, the closing price was at $49.23. For Idera Pharmaceuticals Inc (NASDAQ:IDRA), HC Wainwright & Co. downgraded the previous rating of Buy to Neutral. Idera Pharmaceuticals earned $0.22 in the fourth quarter, compared to $1.36 in the year-ago quarter. At the moment, the stock has a 52-week-high of $6.14 and a 52-week-low of $1.05. Idera Pharmaceuticals closed at $5.21 at the end of the last trading period. JP Morgan downgraded the previous rating for Kimberly-Clark Corp (NYSE:KMB) from Neutral to Underweight. In the fourth quarter, Kimberly-Clark showed an EPS of $1.69, compared to $1.71 from the year-ago quarter. The current stock performance of Kimberly-Clark shows a 52-week-high of $160.16 and a 52-week-low of $110.66. Moreover, at the end of the last trading period, the closing price was at $132.26. According to Jefferies, the prior rating for The Simply Good Foods Co (NASDAQ:SMPL) was changed from Buy to Hold. Simply Good Foods earned $0.29 in the first quarter, compared to $0.22 in the year-ago quarter. The current stock performance of Simply Good Foods shows a 52-week-high of $35.25 and a 52-week-low of $14.08. Moreover, at the end of the last trading period, the closing price was at $32.90. See all analyst ratings downgrades. Initiations With a Buy rating, UBS initiated coverage on LPL Financial Holdings Inc (NASDAQ:LPLA). The price target seems to have been set at $160.00 for LPL Finl Hldgs. For the fourth quarter, LPL Finl Hldgs had an EPS of $1.53, compared to year-ago quarter EPS of $1.68. At the moment, the stock has a 52-week-high of $146.03 and a 52-week-low of $32.01. LPL Finl Hldgs closed at $144.17 at the end of the last trading period. Craig-Hallum initiated coverage on Luminar Technologies Inc (NASDAQ:LAZR) with a Hold rating. The price target for Luminar Technologies is set to $24.00. At the moment, the stock has a 52-week-high of $47.80 and a 52-week-low of $19.10. Luminar Technologies closed at $26.30 at the end of the last trading period. With an Overweight rating, Cantor Fitzgerald initiated coverage on Marker Therapeutics Inc (NASDAQ:MRKR). The price target seems to have been set at $6.00 for Marker Therapeutics. In the fourth quarter, Marker Therapeutics showed an EPS of $0.18, compared to $0.11 from the year-ago quarter. The current stock performance of Marker Therapeutics shows a 52-week-high of $3.77 and a 52-week-low of $1.32. Moreover, at the end of the last trading period, the closing price was at $1.80. Cowen & Co. initiated coverage on Linde PLC (NYSE:LIN) with a Market Perform rating. The price target for Linde is set to $300.00. In the fourth quarter, Linde showed an EPS of $2.30, compared to $1.89 from the year-ago quarter. The current stock performance of Linde shows a 52-week-high of $274.57 and a 52-week-low of $146.80. Moreover, at the end of the last trading period, the closing price was at $268.06. Oppenheimer initiated coverage on Aeva Technologies Inc (NYSE:AEVA) with an Outperform rating. The price target for Aeva Technologies is set to $20.00. At the moment, the stock has a 52-week-high of $18.91 and a 52-week-low of $12.87. Aeva Technologies closed at $13.12 at the end of the last trading period. With a Buy rating, Truist Securities initiated coverage on Aemetis Inc (NASDAQ:AMTX). The price target seems to have been set at $35.00 for Aemetis. Aemetis earned $0.67 in the fourth quarter, compared to $0.33 in the year-ago quarter. At the moment, the stock has a 52-week-high of $21.84 and a 52-week-low of $0.37. Aemetis closed at $18.91 at the end of the last trading period. Cowen & Co. initiated coverage on Air Products & Chemicals Inc (NYSE:APD) with an Outperform rating. The price target for Air Products & Chemicals is set to $340.00. For the first quarter, Air Products & Chemicals had an EPS of $2.12, compared to year-ago quarter EPS of $2.14. The current stock performance of Air Products & Chemicals shows a 52-week-high of $327.89 and a 52-week-low of $173.91. Moreover, at the end of the last trading period, the closing price was at $269.33. With a Equal-Weight rating, Barclays initiated coverage on MultiPlan Corp (NYSE:MPLN). The price target seems to have been set at $7.00 for MultiPlan. Interestingly, in the fourth quarter, MultiPlan's EPS was $0.22. At the moment, the stock has a 52-week-high of $9.82 and a 52-week-low of $6.04. MultiPlan closed at $6.11 at the end of the last trading period. Stifel initiated coverage on ARKO Corp (NASDAQ:ARKO) with a Buy rating. The price target for ARKO is set to $12.00. The current stock performance of ARKO shows a 52-week-high of $10.18 and a 52-week-low of $7.58. Moreover, at the end of the last trading period, the closing price was at $9.93. Wolfe Research initiated coverage on Crown Castle International Corp (NYSE:CCI) with a Peer Perform rating. The price target for Crown Castle Intl is set to $165.00. For the fourth quarter, Crown Castle Intl had an EPS of $2.33, compared to year-ago quarter EPS of $1.38. The stock has a 52-week-high of $180.00 and a 52-week-low of $114.18. At the end of the last trading period, Crown Castle Intl closed at $165.17. With a Buy rating, Benchmark initiated coverage on Forum Merger III Corp (NASDAQ:FIII). The price target seems to have been set at $23.00 for Forum Merger III. At the moment, the stock has a 52-week-high of $15.30 and a 52-week-low of $9.67. Forum Merger III closed at $10.24 at the end of the last trading period. DA Davidson initiated coverage on A-Mark Precious Metals Inc (NASDAQ:AMRK) with a Buy rating. The price target for A-Mark Precious Metals is set to $55.00. In the second quarter, A-Mark Precious Metals showed an EPS of $1.16, compared to $0.17 from the year-ago quarter. At the moment, the stock has a 52-week-high of $39.95 and a 52-week-low of $7.77. A-Mark Precious Metals closed at $38.27 at the end of the last trading period. Jefferies initiated coverage on Advent Technologies Holdings Inc (NASDAQ:ADN) with a Buy rating. The price target for Advent Technologies Hldgs is set to $18.00. The stock has a 52-week-high of $17.75 and a 52-week-low of $11.89. At the end of the last trading period, Advent Technologies Hldgs closed at $13.91. Stephens & Co. initiated coverage on Beyond Meat Inc (NASDAQ:BYND) with an Overweight rating. The price target for Beyond Meat is set to $190.00. For the fourth quarter, Beyond Meat had an EPS of $0.34, compared to year-ago quarter EPS of $0.01. The stock has a 52-week-high of $221.00 and a 52-week-low of $48.18. At the end of the last trading period, Beyond Meat closed at $133.72. With a Buy rating, HC Wainwright & Co. initiated coverage on MiMedx Group Inc (NASDAQ:MDXG). The price target seems to have been set at $20.00 for MiMedx Group. MiMedx Group earned $0.16 in the fourth quarter, compared to $0.07 in the year-ago quarter. The stock has a 52-week-high of $11.44 and a 52-week-low of $2.95. At the end of the last trading period, MiMedx Group closed at $8.81. KeyBanc initiated coverage on BTRS Holdings Inc (NASDAQ:BTRS) with an Overweight rating. The price target for BTRS Holdings is set to $20.00. The stock has a 52-week-high of $19.76 and a 52-week-low of $13.52. At the end of the last trading period, BTRS Holdings closed at $16.42. See all analyst ratings initiations. See more from BenzingaClick here for options trades from BenzingaStocks That Hit 52-Week Lows On FridayA Look Into Commercial Metals Price Over Earnings© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.